KLK1 administration inhibited TGF-β-related fibrosis signaling pathways, increased the expression of eNOS as well as ameliorated hypoxia and oxidative stress, and suppressed the proangiogenic VEGF in prostatitis rats. This evidence concerns the gene KLK1 and urogenital neoplasm.